scispace - formally typeset
I

Ioannis Kalomenidis

Researcher at National and Kapodistrian University of Athens

Publications -  117
Citations -  2622

Ioannis Kalomenidis is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Pleural effusion & Malignant pleural effusion. The author has an hindex of 23, co-authored 102 publications receiving 1878 citations. Previous affiliations of Ioannis Kalomenidis include Athens State University & Saint Thomas - West Hospital.

Papers
More filters
Journal ArticleDOI

Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial.

Evdoxia Kyriazopoulou, +64 more
- 03 Sep 2021 - 
TL;DR: The SAVE-MORE trial as discussed by the authors evaluated the efficacy and safety of anakinra, an IL-1α/β inhibitor, in 594 patients with COVID-19 at risk of progressing to respiratory failure.
Journal ArticleDOI

Malignant pleural effusion: from bench to bedside.

Ioannis Psallidas, +4 more
- 01 Jun 2016 - 
TL;DR: This article attempts to provide a comprehensive overview of current advances in MPE from bench to bedside, and highlights unanswered questions in current clinical practice and suggests future directions for basic and clinical research in the field.
Journal ArticleDOI

Comparison of the effects of e-cigarette vapor with cigarette smoke on lung function and inflammation in mice

Constantinos Glynos, +10 more
- 01 Nov 2018 - 
TL;DR: Exposure to e-cig vapor can trigger inflammatory responses and adversely affect respiratory system mechanics and it is concluded that both e- cig vaping and conventional cigarette smoking negatively impact lung biology.
Journal ArticleDOI

Octreotide and chylothorax

Ioannis Kalomenidis
- 01 Jul 2006 - 
TL;DR: Accumulating evidence suggests that octreotide is a putative novel therapeutic intervention for chylothorax, and it is imperative that randomized controlled studies are conducted in order to fully elucidate the efficacy and safety of this treatment.
Journal ArticleDOI

Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial.

Richard T. Davey, +152 more
- 30 Sep 2019 - 
TL;DR: In this article, the authors evaluated the safety and efficacy of intravenous immunoglobulin (HIVIG) in a randomized controlled trial. But, they did not evaluate the effect of the infusion of high-titre hIVIG on clinical outcomes.